November2008

► NEW DRUGS	Standard Plan	Select Plan	Closed Plan
No new drugs were reviewed at the October meetings.

► LINE EXTENSIONS	Standard Plan	Select Plan	Closed Plan
No new line extensions were reviewed at the October meetings.

► DRUG CLASS REVIEW	Standard Plan	Select Plan	Closed Plan
No drug class reviews at the October meetings.

► PPL UPDATES	Standard Plan	Select Plan	Closed Plan
Simcor
Simcor is a combination of simvastatin and extended release niacin indicated for the treatment of primary hypercholesterolemia, mixed dyslipidemia or hypertriglyceridemia when therapy with either agent alone is considered inadequate. Prior therapy review applies as an electronic step edit. The electronic edit reviews claim history for prior use of Advicor or simvastatin. In a limited category (cholesterol lowering) DACON applies Simcor is added to Preferred Brand status, effective January 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second Tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second Tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Avandaryl
Avandaryl is a combination of rosiglitazone maleate (a TZD) and glimepiride (a sulfonylurea). Avandaryl, along with diet and exercise, is used to improve blood sugar control in patients with Type 2 diabetes. Avandaryl is removed from the Preferred Products List (PPL), effective January 1, 2009.	Brand copay.	Third tier, non-preferred brand copay.	Not covered.

► BRANDS WITH GENERICS AVAILABLE	Standard Plan	Select Plan	Closed Plan
No products with new generics were reviewed at October meeting.

► CLINICAL PROGRAMS (DACON)	Standard Plan	Select Plan	Closed Plan
Avapro, Avalide, LiquADD
Listed items will be added to the DACON program, effective January 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second Tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Second Tier, preferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.
Atacand, Atacand-HCT, Cozaar, Hyzaar, Teveten, Teveten-HCT
Listed items will be added to the DACON program, effective January 1, 2009.	Brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Third Tier, nonpreferred brand copay. Coverage determined by the benefit design chosen by the plan sponsor.	Not covered.

	November2008



Innoviant's Business Committee meets monthly to evaluate product status (tier placements) and new prescription products approved by the Food and Drug Administration (FDA). Decisions made by the Innoviant Business Committee are based on information and recommendations provided by Prescription Solutions' National Pharmacy & Therapeutics Committee (NPTC). The P&T is comprised of independent physician providers, affiliated plan physicians and pharmacists. The following table summarizes the decisions made at the October committee meetings. All changes are effective January 1, 2009 unless otherwise noted. Current information related to Innoviant and its offerings is available at http://www.innoviant.com/. A copy of this newsletter can also be found on the website (http://www.innoviant.com/customers/publications/default.asp).